The Patient Insurance Act and the Patient Injuries Act are applicable in cases of bodily injury or loss of life resulting from medical treatment or healthcare received in hospitals, healthcare centers, private clinics, or even outside medical institutions if performed by a medical professional. However, certain conditions must be met, such as the injury occurring within Finland’s geographic area, the limitation period not having expired, and the injured party being a patient or participant in medical research. From 2021, the new Patient Insurance Act applies to health and medical care provided abroad if arranged by a public healthcare unit. The Patient Insurance Centre evaluates the compensability of the injury based on eight grounds.

The Patient Insurance Act and the Patient Injuries Act are applicable in cases of bodily injury or loss of life resulting from medical treatment or healthcare received in hospitals, healthcare centers, private clinics, or even outside medical institutions if performed by a medical professional. However, certain conditions must be met, such as the injury occurring within Finland’s geographic area, the limitation period not having expired, and the injured party being a patient or participant in medical research. From 2021, the new Patient Insurance Act applies to health and medical care provided abroad if arranged by a public healthcare unit. The Patient Insurance Centre evaluates the compensability of the injury based on eight grounds.

Rajasthan has become the first Indian state to pass the Right to Health Bill, sparking calls for health rights to be constitutionalized in India. While the Indian Constitution obliges the state to provide healthcare via Directive Principles of State Policy, these are non-justiciable and non-enforceable. India’s government health expenditure falls short of the National Health Policy’s target of 2.5% of GDP, and out-of-pocket expenditure still accounts for nearly half of total health spending. The article recommends developing legally justiciable public health legislation, requiring significant government investment and stakeholder collaboration, to achieve SDG 3 of good health and well-being while protecting healthcare providers’ rights and considering social, political, and economic factors that impact health.

India’s Attorney General, R. Venkataramani, announced during a hearing challenging WhatsApp’s latest privacy policy that a new Data Protection Bill will be introduced in the Monsoon Session of Parliament in July 2023. The Bill will address the concerns raised in the present petitions. The Bench directed the registry to place the matter before the Hon’ble CJI to constitute a new Constitution Bench in August 2023. The Solicitor General informed the Bench that the Data Protection Bill introduced in Parliament had been withdrawn, and a comprehensive Bill was underway. The hearing was adjourned until February 2023, and WhatsApp was instructed to widely publicize that users in India do not have to accept its 2021 privacy policy to use it.

Junior doctors in England have commenced a four-day strike over pay, leading to an estimated 350,000 cancelled appointments, including operations. The British Medical Association (BMA) members will picket outside hospitals from 7am until Saturday morning in the longest industrial action since last year’s strike by other health workers. The NHS Confederation’s CEO, Matthew Taylor, has urged both sides to end their “battle of rhetoric” as patient care is “very fragile” during the stoppage. NHS England’s National Medical Director, Prof Sir Stephen Powis, added that “cover is very fragile” and the public should use services wisely as routine care would be affected.

New study finds high dose tofacitinib is safe and effective in COVID patients with pneumonitis and may prevent deterioration to respiratory failure. Open-labelled study with 116 patients, 15.5% of tofacitinib group progressed to non-invasive ventilation, compared to 29.3% in control group. Published in European Journal of Clinical Investigation.

New study finds high dose tofacitinib is safe and effective in COVID patients with pneumonitis and may prevent deterioration to respiratory failure. Open-labelled study with 116 patients, 15.5% of tofacitinib group progressed to non-invasive ventilation, compared to 29.3% in control group. Published in European Journal of Clinical Investigation.